Please enter the email address you used to register, then we will send you a link to choose a new password
Lake Street analyst Ben Klieve maintains Evogene (NASDAQ:EVGN) with a Buy and lowers the price target from $5 to $3.5.
Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.63) by 39...
Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological productsREHOVOT, Israel, ...
Evogene (NASDAQ:EVGN) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.72) by 10...
Evogene (NASDAQ:EVGN) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.63) by ...